Skip to content

Enfortumab vedotin

Padcev (enfortumab vedotin) is an antibody pharmaceutical. Enfortumab vedotin was first approved as Padcev on 2019-12-18. It is used to treat urinary bladder neoplasms in the USA. The pharmaceutical is active against nectin-4.
Trade Name Padcev
Common Name Enfortumab vedotin
Indication urinary bladder neoplasms
Drug Class Synthetic analogs of the dolastatin series; monoclonal antibodies: fully human, tumors as target
Enfortumab vedotin
Get full access now